ChondroNest SA develops a patented composition of modified biopolymers from the extracellular matrix designed to reconstruct cartilage. The technology is a surgeon-placeable, shapeable paste that solidifies under biocompatible conditions to reconstruct the ECM scaffold in vivo; the company is pursuing preclinical studies toward applications in hyaline cartilage repair.
AI-generated
Offering
Products & services
Industry:Research & DevelopmentMedical Technology Industry
Outbound Leads by COHAGA
Looking for direct email addresses and phone numbers?
Leadhub delivers verified contact details and decision-makers from over 750,000 Swiss companies — management, procurement, marketing, HR.
Patented composition of modified biopolymers for in-vivo reconstruction of cartilage and the extracellular matrix; developed as a mouldable paste for surgical use.
Development of hyaline cartilage applications
Development of the application of the protected technology for the reconstruction of hyaline cartilage; preclinical tests on animal models for osteochondritis and osteoarthritis are planned.
Licensing medical technology to MedTech companies
After the first preclinical in-man studies, the product is to be licensed to large MedTech companies for sales and marketing; production of the ChondroNest™ pastes remains with the company.
Comparisons
ChondroNest SA in comparison
Soon
Industry comparisons are coming soon
We're preparing industry comparisons that rank ChondroNest SA by reviews, experience and specialisations.
Knowledge
No knowledge articles yet
Once ChondroNest SA has claimed this profile, we'll publish editorial articles and case studies here together.